News

Article

Iontas, Teva Enter New Antibody Optimization Agreement

Iontas and Teva Pharmaceuticals have entered into an agreement for the application of technologies and know-how into the optimization of human antibodies to be used as biotherapeutics.

Biotechnology company, Iontas, and Teva Pharmaceuticals have entered into an agreement for the application of technologies and know-how into the optimization of human antibodies to be used as biotherapeutics.

In a July 29, 2019 press statement, it was revealed that under the terms of the agreement Iontas will initially apply its proprietary technologies to provide Teva with a panel of optimized antibodies against a defined target. Additionally, through the agreement, Teva will also have the option to enter further optimization programs in the future, and options for the screening of biophysical properties suitable for developable antibodiesare also included.

“Our experience in both antibody discovery and optimization enables us to generate antibodies that meet the stringent characteristics required by our partners and the selection of IONTAS by Teva is a validation of this know-how and expertise,” said Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, in the press statement. “With our ability to focus on function, affinity, specificity, and developability, we can generate lead antibodies with lower risk of chemistry, manufacturing, and controls issues.”

Source: Iontas

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content